N Engl J Med:缓解干眼症 鱼油遭打脸

2018-06-24 MedSci 环球医学网

干眼症是临床上较常见的一种眼部疾病,患者会出现各种眼部不适症状,严重时甚至影响视觉功能。发表在《N Engl J Med》的一项多中心、双盲临床研究调查了n?3脂肪酸补充剂(通常叫做ω-3脂肪酸)治疗干眼症的疗效。

干眼症是临床上较常见的一种眼部疾病,患者会出现各种眼部不适症状,严重时甚至影响视觉功能。发表在《N Engl J Med》的一项多中心、双盲临床研究调查了n?3脂肪酸补充剂(通常叫做ω-3脂肪酸)治疗干眼症的疗效。

背景:干眼症是一种常见的慢性病,以眼部不适和视觉受阻为特征,进而降低生活质量。许多临床医师推荐使用n?3脂肪酸补充剂来缓解症状。

方法:在一项多中心、双盲临床研究中,研究者将中至重度干眼症患者随机分配至每天口服3000 mg鱼类n?3二十碳五烯酸和二十二碳六烯酸(积极补充组)或橄榄油安慰剂(安慰剂组)。主要结局指标为基于6个月和12个月评分平均值,眼表疾病指数(OSDI;评分范围0~100,评分越高显示症状严重程度越大)与基线相比的平均变化。次要结局指标包括每只眼睛结膜染色评分(范围:0~6)和角膜染色评分(范围:0~15)的平均变化,评分越高说明眼表损害越严重,以及泪膜破裂时间(眨眼的秒数和泪液膜裂痕)的平均变化,以及Schirmer测试的结果(下眼睑上放置的纸带的润湿长度),数值越低说明病情越严重。

结果:共有349例患者被分配至积极补充组,186例患者分配至安慰剂组;主要分析分别包括329例和170例患者。积极补充组与安慰剂组的OSDI评分平均变化没有显着差异(分别为?13.9分和?12.5分;在填补缺失的数据后变化的平均差异,?1.9分;95%置信区间[CI],?5.0~1.1;P=0.21)。预定亚组之间的结果具有一致性。积极补充组与安慰剂组在结膜染色评分(变化的平均差异,0.0分;95% CI,?0.2~0.1)、角膜染色评分(0.1分;95% CI,?0.2~0.4)、泪膜破裂时间(0.2秒;95% CI,?0.1~0.5)和Schirmer测试的结果(0.0 mm;95% CI,?0.8~0.9)方面与基线相比的平均变化没有显着差异。根据红细胞中n?3脂肪酸的水平,12个月时,积极补充组的依从率为85.2%。两组之间的不良事件率相似。

结果:在干眼症患者中,被随机分配至使用富含3000 mg n?3脂肪酸补充剂为期12个月的患者,其结局并不显着优于分配至使用安慰剂的患者。

原始出处:
Dry Eye Assessment and Management Study Research Group, Asbell PA, Maguire MG,et al.n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.N Engl J Med. 2018 May 3;378(18):1681-1690. doi: 10.1056/NEJMoa1709691. Epub 2018 Apr 13.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081465, encodeId=5f6520814652f, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Apr 24 10:33:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785522, encodeId=1a9b1e8552291, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Aug 03 09:33:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376843, encodeId=15cf13e6843d2, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527319, encodeId=ca96152e319c7, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608895, encodeId=3afb16088954d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326858, encodeId=25a0326858d5, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jun 25 09:03:28 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326616, encodeId=49963266169e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Jun 24 11:26:53 CST 2018, time=2018-06-24, status=1, ipAttribution=)]
    2019-04-24 spoonycyy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081465, encodeId=5f6520814652f, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Apr 24 10:33:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785522, encodeId=1a9b1e8552291, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Aug 03 09:33:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376843, encodeId=15cf13e6843d2, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527319, encodeId=ca96152e319c7, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608895, encodeId=3afb16088954d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326858, encodeId=25a0326858d5, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jun 25 09:03:28 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326616, encodeId=49963266169e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Jun 24 11:26:53 CST 2018, time=2018-06-24, status=1, ipAttribution=)]
    2018-08-03 haouestc
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081465, encodeId=5f6520814652f, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Apr 24 10:33:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785522, encodeId=1a9b1e8552291, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Aug 03 09:33:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376843, encodeId=15cf13e6843d2, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527319, encodeId=ca96152e319c7, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608895, encodeId=3afb16088954d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326858, encodeId=25a0326858d5, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jun 25 09:03:28 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326616, encodeId=49963266169e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Jun 24 11:26:53 CST 2018, time=2018-06-24, status=1, ipAttribution=)]
    2018-06-25 yeaweam
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081465, encodeId=5f6520814652f, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Apr 24 10:33:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785522, encodeId=1a9b1e8552291, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Aug 03 09:33:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376843, encodeId=15cf13e6843d2, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527319, encodeId=ca96152e319c7, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608895, encodeId=3afb16088954d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326858, encodeId=25a0326858d5, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jun 25 09:03:28 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326616, encodeId=49963266169e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Jun 24 11:26:53 CST 2018, time=2018-06-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2081465, encodeId=5f6520814652f, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Apr 24 10:33:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785522, encodeId=1a9b1e8552291, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Aug 03 09:33:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376843, encodeId=15cf13e6843d2, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527319, encodeId=ca96152e319c7, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608895, encodeId=3afb16088954d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326858, encodeId=25a0326858d5, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jun 25 09:03:28 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326616, encodeId=49963266169e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Jun 24 11:26:53 CST 2018, time=2018-06-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2081465, encodeId=5f6520814652f, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Apr 24 10:33:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785522, encodeId=1a9b1e8552291, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Aug 03 09:33:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376843, encodeId=15cf13e6843d2, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527319, encodeId=ca96152e319c7, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608895, encodeId=3afb16088954d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326858, encodeId=25a0326858d5, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jun 25 09:03:28 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326616, encodeId=49963266169e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Jun 24 11:26:53 CST 2018, time=2018-06-24, status=1, ipAttribution=)]
    2018-06-25 明月清辉

    谢谢分享.学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2081465, encodeId=5f6520814652f, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Apr 24 10:33:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785522, encodeId=1a9b1e8552291, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Aug 03 09:33:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376843, encodeId=15cf13e6843d2, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527319, encodeId=ca96152e319c7, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608895, encodeId=3afb16088954d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 25 23:33:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326858, encodeId=25a0326858d5, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jun 25 09:03:28 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326616, encodeId=49963266169e, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Jun 24 11:26:53 CST 2018, time=2018-06-24, status=1, ipAttribution=)]
    2018-06-24 明月清辉

    谢谢分享.学习了

    0

相关资讯

Semin Arthritis Rheu:靶向治疗策略对早期类风湿性关节炎骨侵蚀进展的影响

尽管更严格的治疗目标并未显著影响临床治疗结局和1年时的侵蚀进展,但达到持续SDAI缓解与部分侵蚀修复相关。

Ann Rheum Dis:类风湿性关节炎患者托珠单抗或联合甲氨蝶呤治疗缓解后的托珠单抗停药

在一半以上的患者中,托珠单抗停药后的持续低疾病活动性可以通过继续使用甲氨喋呤得到维持。重新使用托珠单抗使超过90%的患者得到缓解。

Arthritis Rheumatol:戈利木单抗诱导治疗早期外周脊柱关节炎后的无药缓解率高

超早期pSpA进行抗TNF治疗可产生很高的持续临床缓解率。停药后超过50%的患者仍处于缓解状态。

Arthritis Rheumatol:系统性红斑狼疮缓解和低疾病活动状态预防损害的比较

LLDAS是一个比治疗临床缓解更容易实现的目标,并且可以减少长期损害的风险。

缓解儿科医生荒 各省市都有何妙招?

儿科医生短缺是我国各个省市都存在的问题,去年冬季的一场流感,更让儿科医生短缺的现状不容忽视,情势严峻。为响应国家号召,各个省市纷纷出台了补齐儿科医生短板的措施。日前,武汉首批儿科转岗医生已进入武汉儿童医院,经过一年的培训后,补充到紧缺的临床一线。

J Rheumatol:狼疮性肾炎患者的肾脏缓解状况和长期肾脏存活情况

LN诊断后24个月的肾脏缓解状态是长期肾脏存活的重要预测指标。